JPWO2021055747A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021055747A5 JPWO2021055747A5 JP2022516684A JP2022516684A JPWO2021055747A5 JP WO2021055747 A5 JPWO2021055747 A5 JP WO2021055747A5 JP 2022516684 A JP2022516684 A JP 2022516684A JP 2022516684 A JP2022516684 A JP 2022516684A JP WO2021055747 A5 JPWO2021055747 A5 JP WO2021055747A5
- Authority
- JP
- Japan
- Prior art keywords
- alk
- optionally substituted
- alkyl
- group
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962902554P | 2019-09-19 | 2019-09-19 | |
| US62/902,554 | 2019-09-19 | ||
| US202063078055P | 2020-09-14 | 2020-09-14 | |
| US63/078,055 | 2020-09-14 | ||
| PCT/US2020/051491 WO2021055747A1 (en) | 2019-09-19 | 2020-09-18 | Therapeutic conjugates |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022548135A JP2022548135A (ja) | 2022-11-16 |
| JPWO2021055747A5 true JPWO2021055747A5 (https=) | 2023-09-27 |
| JP2022548135A5 JP2022548135A5 (https=) | 2023-09-27 |
| JP7810640B2 JP7810640B2 (ja) | 2026-02-03 |
Family
ID=74883745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022516684A Active JP7810640B2 (ja) | 2019-09-19 | 2020-09-18 | 治療用コンジュゲート |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20220387603A1 (https=) |
| EP (1) | EP4031143B1 (https=) |
| JP (1) | JP7810640B2 (https=) |
| KR (1) | KR20220079866A (https=) |
| CN (2) | CN120789282A (https=) |
| AU (1) | AU2020349543A1 (https=) |
| BR (1) | BR112022005026A2 (https=) |
| CA (1) | CA3154079A1 (https=) |
| CL (1) | CL2022000665A1 (https=) |
| CO (1) | CO2022003703A2 (https=) |
| DK (1) | DK4031143T3 (https=) |
| ES (1) | ES3043134T3 (https=) |
| IL (1) | IL291486B1 (https=) |
| MX (1) | MX2022003217A (https=) |
| PE (1) | PE20230091A1 (https=) |
| PH (1) | PH12022550494A1 (https=) |
| TW (1) | TWI870468B (https=) |
| WO (1) | WO2021055747A1 (https=) |
| ZA (1) | ZA202203201B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220079866A (ko) | 2019-09-19 | 2022-06-14 | 토투스 메디신스 아이엔씨. | 치료 접합체 |
| WO2022198024A1 (en) * | 2021-03-18 | 2022-09-22 | Totus Medicines Inc. | Therapeutic conjugates |
| WO2023183936A2 (en) * | 2022-03-24 | 2023-09-28 | Totus Medicines Inc. | Combination therapy of a pi3k inhibitor and kras inhibitor and methods of use thereof |
| AU2023240100A1 (en) | 2022-03-24 | 2024-10-03 | Totus Medicines Inc. | Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof |
| AU2023249795A1 (en) | 2022-04-08 | 2024-10-17 | Shy Therapeutics, Llc | Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| WO2024086664A2 (en) * | 2022-10-18 | 2024-04-25 | Totus Medicines Inc. | Covalent inhibitors of wild-type and mutant pi3k and method of uses thereof |
| WO2024220380A2 (en) * | 2023-04-16 | 2024-10-24 | Totus Medicines Inc. | Pi3k assays and probe compounds therein |
| EP4704841A1 (en) | 2023-05-05 | 2026-03-11 | Eli Lilly and Company | Imlunestrant or salts thereof for use in treating and preventing central nervous system (cns) metastases in subjects having er+ breast cancer |
| CN117126164B (zh) * | 2023-08-30 | 2024-09-27 | 山东轩硕医药科技有限公司 | 一种吡咯并三嗪类化合物，其制备方法及用途 |
| WO2025072796A1 (en) * | 2023-09-27 | 2025-04-03 | Totus Medicines Inc. | Pharmaceutical compositions and methods of use thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585245A (en) | 1994-04-22 | 1996-12-17 | California Institute Of Technology | Ubiquitin-based split protein sensor |
| US6342345B1 (en) | 1997-04-02 | 2002-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of molecular interactions by reporter subunit complementation |
| US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| WO2009023179A2 (en) | 2007-08-10 | 2009-02-19 | Genelabs Technologies, Inc. | Nitrogen containing bicyclic chemical entities for treating viral infections |
| ES2660418T3 (es) * | 2008-07-16 | 2018-03-22 | Pharmacyclics Llc | Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos |
| US20100204265A1 (en) | 2009-02-09 | 2010-08-12 | Genelabs Technologies, Inc. | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections |
| EP2475375A4 (en) * | 2009-09-09 | 2013-02-20 | Avila Therapeutics Inc | PI3 KINASE INHIBITORS AND USES THEREOF |
| EP2526102B1 (en) | 2010-01-22 | 2017-03-08 | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | Inhibitors of PI3 kinase |
| US20130131057A1 (en) | 2010-05-13 | 2013-05-23 | Centro Nacional De Investigaciones Oncologicas (Cnio | New bicyclic compounds as pi3-k and mtor inhibitors |
| AU2011258005A1 (en) | 2010-05-28 | 2013-01-17 | Biocryst Pharmaceuticals, Inc. | Heterocyclic compounds as Janus kinase inhibitors |
| US20120231963A1 (en) | 2011-03-10 | 2012-09-13 | Raybiotech, Inc, | Biotin-label-based antibody array for high-content profiling of protein expression |
| CA2836449C (en) * | 2011-05-17 | 2021-04-27 | The Regents Of The University Of California | Kinase inhibitors |
| EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
| US9724352B2 (en) * | 2012-05-31 | 2017-08-08 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof |
| CN103450204B (zh) * | 2012-05-31 | 2016-08-17 | 中国科学院上海药物研究所 | 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途 |
| CN102675323B (zh) | 2012-06-01 | 2014-04-09 | 南京药石药物研发有限公司 | 吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途 |
| KR102420322B1 (ko) | 2014-06-17 | 2022-07-13 | 키에시 파르마슈티시 엣스. 피. 에이. | 포스포이노시타이드 3-키나아제 억제제로서 인돌리진 유도체 |
| ES2771926T3 (es) * | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| WO2017004134A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CN109111447A (zh) * | 2017-06-23 | 2019-01-01 | 中国科学院上海药物研究所 | 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途 |
| US12291533B2 (en) | 2017-08-02 | 2025-05-06 | Northwestern University | Substituted fused pyrimidine compounds and uses thereof |
| WO2019113523A1 (en) | 2017-12-08 | 2019-06-13 | Ashok Bajji | Compounds and therapeutic uses thereof |
| CN109081905A (zh) | 2018-08-03 | 2018-12-25 | 浩力森涂料（上海）有限公司 | 水性环氧固化剂及其制备方法 |
| WO2020052772A1 (en) | 2018-09-13 | 2020-03-19 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Modulation of trf1 for brain cancer treatment |
| WO2020243457A1 (en) | 2019-05-29 | 2020-12-03 | Viogen Biosciences, Llc | Compounds and therapeutic uses thereof |
| KR20220079866A (ko) | 2019-09-19 | 2022-06-14 | 토투스 메디신스 아이엔씨. | 치료 접합체 |
| EP4165045A4 (en) | 2020-06-05 | 2024-07-03 | Monash University | DOUBLE KINASE-BROMODOMAIN INHIBITORS |
| US20230285498A1 (en) | 2020-08-07 | 2023-09-14 | City Of Hope | Treatments for cancers having kras mutations |
| WO2022198024A1 (en) | 2021-03-18 | 2022-09-22 | Totus Medicines Inc. | Therapeutic conjugates |
| WO2023183936A2 (en) | 2022-03-24 | 2023-09-28 | Totus Medicines Inc. | Combination therapy of a pi3k inhibitor and kras inhibitor and methods of use thereof |
| AU2023240100A1 (en) | 2022-03-24 | 2024-10-03 | Totus Medicines Inc. | Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof |
-
2020
- 2020-09-18 KR KR1020227012813A patent/KR20220079866A/ko active Pending
- 2020-09-18 BR BR112022005026A patent/BR112022005026A2/pt not_active IP Right Cessation
- 2020-09-18 US US17/642,945 patent/US20220387603A1/en active Pending
- 2020-09-18 MX MX2022003217A patent/MX2022003217A/es unknown
- 2020-09-18 DK DK20865745.2T patent/DK4031143T3/da active
- 2020-09-18 PE PE2022000435A patent/PE20230091A1/es unknown
- 2020-09-18 EP EP20865745.2A patent/EP4031143B1/en active Active
- 2020-09-18 AU AU2020349543A patent/AU2020349543A1/en active Pending
- 2020-09-18 TW TW109132462A patent/TWI870468B/zh active
- 2020-09-18 JP JP2022516684A patent/JP7810640B2/ja active Active
- 2020-09-18 ES ES20865745T patent/ES3043134T3/es active Active
- 2020-09-18 WO PCT/US2020/051491 patent/WO2021055747A1/en not_active Ceased
- 2020-09-18 CA CA3154079A patent/CA3154079A1/en active Pending
- 2020-09-18 CN CN202510512926.7A patent/CN120789282A/zh active Pending
- 2020-09-18 CN CN202080074001.4A patent/CN114599366B/zh active Active
- 2020-09-18 PH PH1/2022/550494A patent/PH12022550494A1/en unknown
-
2022
- 2022-03-14 US US17/694,592 patent/US11484597B2/en active Active
- 2022-03-17 ZA ZA2022/03201A patent/ZA202203201B/en unknown
- 2022-03-18 CL CL2022000665A patent/CL2022000665A1/es unknown
- 2022-03-18 IL IL291486A patent/IL291486B1/en unknown
- 2022-03-28 CO CONC2022/0003703A patent/CO2022003703A2/es unknown
- 2022-09-28 US US17/955,182 patent/US12029791B2/en active Active
-
2024
- 2024-07-03 US US18/763,741 patent/US20240366771A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021203182B2 (en) | Functionalized polymers | |
| JPWO2021055747A5 (https=) | ||
| JP4638410B2 (ja) | スフィンゴシン−１−ホスフェートレセプターモジュレーターとしての、アミノプロパノール誘導体 | |
| US11248012B2 (en) | Phospholipidation of imidazoquinolines and oxoadenines | |
| JP7306263B2 (ja) | オリゴヌクレオチドの製造方法 | |
| EP4473980A3 (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers | |
| JP2020530007A5 (https=) | ||
| RU2007106935A (ru) | Производные гуанидина и их терапевтическое применение | |
| CS229919B2 (en) | Production method of coordination compound of platinum | |
| JP2008517949A5 (https=) | ||
| WO2017183217A1 (ja) | ５－アザシチジン類の糖部シリルエーテル誘導体 | |
| NL9002742A (nl) | Glycerolderivaten, werkwijze voor het bereiden daarvan en therapeutische preparaten, die ze bevatten. | |
| JP2007516244A5 (https=) | ||
| JP2021532183A5 (https=) | ||
| JP2020519568A5 (https=) | ||
| PT89082B (pt) | Processo para a preparacao de novos derivados n-(23-vinblastinoilicos) do acido 1-amino-metilfosfonico | |
| JPWO2022029617A5 (https=) | ||
| JP3068143B2 (ja) | アシル化法 | |
| JPWO2021007402A5 (https=) | ||
| CN104860898B (zh) | 3‑芳基噁二唑类化合物及其用途 | |
| WO2009113543A1 (ja) | ホスフィン化合物、その製造方法およびそれを用いた過酸化物捕捉剤 | |
| JPWO2020028461A5 (https=) | ||
| JPWO2023043923A5 (https=) | ||
| FI3441386T3 (fi) | Menetelmä yksöissuojattujen bifunktionaalisten aihiolääkkeiden syntetisoimiseksi ja niihin perustuvia vasta-aine-lääkekonjugaatteja sekä menetelmä vasta-aine-lääkekonjugaattien valmistamiseksi | |
| WO2026089784A2 (en) | Compounds and compositions for conjugation to bioligands for imaging and radiopharmaceutical applications |